Guan Y, Zhang Y, Hao L, et al. - Given that chemotherapeutic cisplatin represents one of the major therapeutic choices in the management of patients with treating advanced hepatocellular carcinoma (HCC), and although there exists several reports on HCC multidrug resistance, there is still a lack of clarity regarding the underlying regulatory mechanisms, so, to explore this topic, researchers assessed circRNA_102272, miR-326 and RUNX2 expression in this study. To verify complementary combinations between circRNA_102272 and miR-326 and between miR-326 and RUNX2, experts used luciferase reporter assay. Findings revealed significantly increased circRNA_102272 in HCC tissues and cells, and HCC cell proliferation and cisplatin-resistance were promoted by circRNA_102272. Notably, circRNA behaved as a ceRNA to suppress the expression as well as activity of miR-326, resulting in the increment in RUNX2 expression.